Ocugen Inc., a biotechnology company specializing in gene therapies for blindness diseases, has announced progress in its clinical trials and upcoming presentations. The company is nearing the completion of enrollment for the OCU400 Phase 3 liMeliGhT clinical trial, with plans to file a Biologics License Application $(BLA.AU)$ by mid-2026. Additionally, Ocugen will present at the 2025 BIO International Convention, taking place from June 16-19 in Boston. During the convention, Ocugen's leadership will engage with potential partners and discuss its novel gene therapy platform. Dr. Shankar Musunuri, Chairman, CEO, and Co-founder, will present on June 16 and participate in panel discussions on June 17 and 18. Results from the clinical trials have not yet been presented and will be shared in the future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.